View:
Download DOC
Download PDF
Download XLS
Download XBRL
abbv-20220630
0001551152falseDecember 312022Q2100015511522022-01-012022-06-300001551152exch:XCHIus-gaap:CommonStockMember2022-01-012022-06-300001551152exch:XNYSus-gaap:CommonStockMember2022-01-012022-06-300001551152exch:XNYSabbv:Sec1500SeniorNotesDue2023Member2022-01-012022-06-300001551152abbv:Sec1.375SeniorNotesDue2024Memberexch:XNYS2022-01-012022-06-300001551152abbv:Sec1250SeniorNotesDue2024Memberexch:XNYS2022-01-012022-06-300001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2022-01-012022-06-300001551152exch:XNYSabbv:Sec2.125SeniorNotesdue2028Member2022-01-012022-06-300001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2022-01-012022-06-300001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2022-01-012022-06-300001551152exch:XNYSabbv:Sec1.250SeniorNotesdue2031Member2022-01-012022-06-3000015511522022-07-27xbrli:shares00015511522022-04-012022-06-30iso4217:USD00015511522021-04-012021-06-3000015511522021-01-012021-06-30iso4217:USDxbrli:shares00015511522022-06-3000015511522021-12-310001551152us-gaap:CommonStockMember2021-03-310001551152us-gaap:TreasuryStockMember2021-03-310001551152us-gaap:AdditionalPaidInCapitalMember2021-03-310001551152us-gaap:RetainedEarningsMember2021-03-310001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001551152us-gaap:NoncontrollingInterestMember2021-03-3100015511522021-03-310001551152us-gaap:CommonStockMember2021-04-012021-06-300001551152us-gaap:TreasuryStockMember2021-04-012021-06-300001551152us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001551152us-gaap:RetainedEarningsMember2021-04-012021-06-300001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001551152us-gaap:NoncontrollingInterestMember2021-04-012021-06-300001551152us-gaap:CommonStockMember2021-06-300001551152us-gaap:TreasuryStockMember2021-06-300001551152us-gaap:AdditionalPaidInCapitalMember2021-06-300001551152us-gaap:RetainedEarningsMember2021-06-300001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001551152us-gaap:NoncontrollingInterestMember2021-06-3000015511522021-06-300001551152us-gaap:CommonStockMember2022-03-310001551152us-gaap:TreasuryStockMember2022-03-310001551152us-gaap:AdditionalPaidInCapitalMember2022-03-310001551152us-gaap:RetainedEarningsMember2022-03-310001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001551152us-gaap:NoncontrollingInterestMember2022-03-3100015511522022-03-310001551152us-gaap:CommonStockMember2022-04-012022-06-300001551152us-gaap:TreasuryStockMember2022-04-012022-06-300001551152us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001551152us-gaap:RetainedEarningsMember2022-04-012022-06-300001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001551152us-gaap:NoncontrollingInterestMember2022-04-012022-06-300001551152us-gaap:CommonStockMember2022-06-300001551152us-gaap:TreasuryStockMember2022-06-300001551152us-gaap:AdditionalPaidInCapitalMember2022-06-300001551152us-gaap:RetainedEarningsMember2022-06-300001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001551152us-gaap:NoncontrollingInterestMember2022-06-300001551152us-gaap:CommonStockMember2020-12-310001551152us-gaap:TreasuryStockMember2020-12-310001551152us-gaap:AdditionalPaidInCapitalMember2020-12-310001551152us-gaap:RetainedEarningsMember2020-12-310001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001551152us-gaap:NoncontrollingInterestMember2020-12-3100015511522020-12-310001551152us-gaap:CommonStockMember2021-01-012021-06-300001551152us-gaap:TreasuryStockMember2021-01-012021-06-300001551152us-gaap:AdditionalPaidInCapitalMember2021-01-012021-06-300001551152us-gaap:RetainedEarningsMember2021-01-012021-06-300001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300001551152us-gaap:NoncontrollingInterestMember2021-01-012021-06-300001551152us-gaap:CommonStockMember2021-12-310001551152us-gaap:TreasuryStockMember2021-12-310001551152us-gaap:AdditionalPaidInCapitalMember2021-12-310001551152us-gaap:RetainedEarningsMember2021-12-310001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001551152us-gaap:NoncontrollingInterestMember2021-12-310001551152us-gaap:CommonStockMember2022-01-012022-06-300001551152us-gaap:TreasuryStockMember2022-01-012022-06-300001551152us-gaap:AdditionalPaidInCapitalMember2022-01-012022-06-300001551152us-gaap:RetainedEarningsMember2022-01-012022-06-300001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300001551152us-gaap:NoncontrollingInterestMember2022-01-012022-06-300001551152us-gaap:InProcessResearchAndDevelopmentMemberus-gaap:CollaborativeArrangementMemberabbv:SyndesiMember2022-01-012022-03-310001551152us-gaap:CollaborativeArrangementMembersrt:MaximumMemberabbv:SyndesiMember2022-02-280001551152abbv:JuvisePharmaceuticalsMember2022-04-012022-06-300001551152us-gaap:OtherOperatingIncomeExpenseMemberabbv:JuvisePharmaceuticalsMember2022-04-012022-06-300001551152us-gaap:CollaborativeArrangementMemberabbv:JanssenBiotechIncMember2022-06-300001551152us-gaap:CollaborativeArrangementMemberabbv:JanssenBiotechIncMember2022-01-012022-06-30xbrli:pure0001551152abbv:JanssenBiotechIncMember2022-01-012022-06-300001551152country:USus-gaap:CollaborativeArrangementMemberabbv:JanssenBiotechIncMember2022-04-012022-06-300001551152country:USus-gaap:CollaborativeArrangementMemberabbv:JanssenBiotechIncMember2021-04-012021-06-300001551152country:USus-gaap:CollaborativeArrangementMemberabbv:JanssenBiotechIncMember2022-01-012022-06-300001551152country:USus-gaap:CollaborativeArrangementMemberabbv:JanssenBiotechIncMember2021-01-012021-06-300001551152us-gaap:NonUsMemberus-gaap:CollaborativeArrangementMemberabbv:JanssenBiotechIncMember2022-04-012022-06-300001551152us-gaap:NonUsMemberus-gaap:CollaborativeArrangementMemberabbv:JanssenBiotechIncMember2021-04-012021-06-300001551152us-gaap:NonUsMemberus-gaap:CollaborativeArrangementMemberabbv:JanssenBiotechIncMember2022-01-012022-06-300001551152us-gaap:NonUsMemberus-gaap:CollaborativeArrangementMemberabbv:JanssenBiotechIncMember2021-01-012021-06-300001551152us-gaap:CollaborativeArrangementMemberabbv:JanssenBiotechIncMember2022-04-012022-06-300001551152us-gaap:CollaborativeArrangementMemberabbv:JanssenBiotechIncMember2021-04-012021-06-300001551152us-gaap:CollaborativeArrangementMemberabbv:JanssenBiotechIncMember2021-01-012021-06-300001551152us-gaap:CollaborativeArrangementMemberabbv:JanssenBiotechIncMember2021-12-310001551152abbv:GenentechInc.Member2022-01-012022-06-300001551152us-gaap:CollaborativeArrangementMemberabbv:GenentechInc.Member2022-04-012022-06-300001551152us-gaap:CollaborativeArrangementMemberabbv:GenentechInc.Member2021-04-012021-06-300001551152us-gaap:CollaborativeArrangementMemberabbv:GenentechInc.Member2022-01-012022-06-300001551152us-gaap:CollaborativeArrangementMemberabbv:GenentechInc.Member2021-01-012021-06-300001551152country:USus-gaap:CollaborativeArrangementMemberabbv:GenentechInc.Member2022-04-012022-06-300001551152country:USus-gaap:CollaborativeArrangementMemberabbv:GenentechInc.Member2021-04-012021-06-300001551152country:USus-gaap:CollaborativeArrangementMemberabbv:GenentechInc.Member2022-01-012022-06-300001551152country:USus-gaap:CollaborativeArrangementMemberabbv:GenentechInc.Member2021-01-012021-06-300001551152us-gaap:DevelopedTechnologyRightsMember2022-06-300001551152us-gaap:DevelopedTechnologyRightsMember2021-12-310001551152us-gaap:LicensingAgreementsMember2022-06-300001551152us-gaap:LicensingAgreementsMember2021-12-310001551152abbv:AllerganIntegrationPlanMember2022-06-300001551152abbv:AllerganIntegrationPlanMember2022-01-012022-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:CostOfSalesMemberus-gaap:EmployeeSeveranceMember2022-04-012022-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:CostOfSalesMemberus-gaap:EmployeeSeveranceMember2021-04-012021-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:CostOfSalesMemberus-gaap:EmployeeSeveranceMember2022-01-012022-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:CostOfSalesMemberus-gaap:EmployeeSeveranceMember2021-01-012021-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:CostOfSalesMemberus-gaap:OtherRestructuringMember2022-04-012022-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:CostOfSalesMemberus-gaap:OtherRestructuringMember2021-04-012021-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:CostOfSalesMemberus-gaap:OtherRestructuringMember2022-01-012022-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:CostOfSalesMemberus-gaap:OtherRestructuringMember2021-01-012021-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:EmployeeSeveranceMember2022-04-012022-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:EmployeeSeveranceMember2021-04-012021-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:EmployeeSeveranceMember2022-01-012022-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:EmployeeSeveranceMember2021-01-012021-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-04-012022-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-04-012021-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeSeveranceMember2022-04-012022-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeSeveranceMember2021-04-012021-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeSeveranceMember2022-01-012022-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeSeveranceMember2021-01-012021-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:OtherRestructuringMember2022-04-012022-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:OtherRestructuringMember2021-04-012021-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:OtherRestructuringMember2022-01-012022-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:OtherRestructuringMember2021-01-012021-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:EmployeeSeveranceMember2022-04-012022-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:EmployeeSeveranceMember2021-04-012021-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:EmployeeSeveranceMember2022-01-012022-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:EmployeeSeveranceMember2021-01-012021-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2022-04-012022-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2021-04-012021-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2022-01-012022-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2021-01-012021-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:EmployeeSeveranceMember2021-12-310001551152abbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2021-12-310001551152abbv:AllerganIntegrationPlanMemberus-gaap:EmployeeSeveranceMember2022-06-300001551152abbv:AllerganIntegrationPlanMemberus-gaap:OtherRestructuringMember2022-06-300001551152abbv:OtherRestructuringPlansMember2022-04-012022-06-300001551152abbv:OtherRestructuringPlansMember2022-01-012022-06-300001551152abbv:OtherRestructuringPlansMember2021-04-012021-06-300001551152abbv:OtherRestructuringPlansMember2021-01-012021-06-300001551152abbv:OtherRestructuringPlansMember2021-12-310001551152abbv:OtherRestructuringPlansMember2022-06-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-06-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-12-310001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-01-012022-06-300001551152us-gaap:TreasuryLockMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2019-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2022-06-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2021-12-310001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2022-06-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2021-12-310001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2022-06-30iso4217:EUR0001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2021-12-310001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:SeniorNotesMember2021-12-310001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:SeniorNotesMember2022-06-300001551152us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-06-300001551152us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-12-310001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2022-06-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2021-12-310001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2022-06-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2021-12-310001551152us-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-06-300001551152us-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-12-310001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:OtherLiabilitiesMember2022-06-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:OtherLiabilitiesMember2021-12-310001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2022-06-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2021-12-310001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2022-06-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2021-12-310001551152us-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2022-06-300001551152us-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2021-12-310001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:OtherLiabilitiesMember2022-06-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:OtherLiabilitiesMember2021-12-310001551152us-gaap:ForeignExchangeForwardMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMember2022-06-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMember2021-12-310001551152us-gaap:ForeignExchangeForwardMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:NondesignatedMember2022-06-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:NondesignatedMember2021-12-310001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:InterestRateSwapMember2022-06-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:InterestRateSwapMember2021-12-310001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:InterestRateSwapMember2022-06-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:InterestRateSwapMember2021-12-310001551152us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:InterestRateSwapMember2022-06-300001551152us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:InterestRateSwapMember2021-12-310001551152us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:InterestRateSwapMember2022-06-300001551152us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:InterestRateSwapMember2021-12-310001551152us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-06-300001551152us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-12-310001551152us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherLiabilitiesMemberus-gaap:InterestRateSwapMember2022-06-300001551152us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherLiabilitiesMemberus-gaap:InterestRateSwapMember2021-12-310001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-04-012022-06-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-04-012021-06-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-06-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-06-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-04-012022-06-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-04-012021-06-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-01-012022-06-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-01-012021-06-300001551152us-gaap:CostOfSalesMember2022-06-300001551152us-gaap:InterestExpenseMember2022-06-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SeniorNotesMember2022-04-012022-06-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SeniorNotesMember2022-01-012022-06-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SeniorNotesMember2021-04-012021-06-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SeniorNotesMember2021-01-012021-06-300001551152us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-04-012022-06-300001551152us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-04-012021-06-300001551152us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-01-012022-06-300001551152us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-01-012021-06-300001551152us-gaap:InterestExpenseMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2022-04-012022-06-300001551152us-gaap:InterestExpenseMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2021-04-012021-06-300001551152us-gaap:InterestExpenseMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2022-01-012022-06-300001551152us-gaap:InterestExpenseMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2021-01-012021-06-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:ForeignCurrencyGainLossMemberus-gaap:NondesignatedMember2022-04-012022-06-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:ForeignCurrencyGainLossMemberus-gaap:NondesignatedMember2021-04-012021-06-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:ForeignCurrencyGainLossMemberus-gaap:NondesignatedMember2022-01-012022-06-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:ForeignCurrencyGainLossMemberus-gaap:NondesignatedMember2021-01-012021-06-300001551152us-gaap:InterestExpenseMemberus-gaap:TreasuryLockMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-04-012022-06-300001551152us-gaap:InterestExpenseMemberus-gaap:TreasuryLockMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-04-012021-06-300001551152us-gaap:InterestExpenseMemberus-gaap:TreasuryLockMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-01-012022-06-300001551152us-gaap:InterestExpenseMemberus-gaap:TreasuryLockMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-01-012021-06-300001551152us-gaap:InterestExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2022-04-012022-06-300001551152us-gaap:InterestExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2021-04-012021-06-300001551152us-gaap:InterestExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2022-01-012022-06-300001551152us-gaap:InterestExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2021-01-012021-06-300001551152us-gaap:InterestExpenseMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-04-012022-06-300001551152us-gaap:InterestExpenseMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-04-012021-06-300001551152us-gaap:InterestExpenseMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-01-012022-06-300001551152us-gaap:InterestExpenseMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-01-012021-06-300001551152us-gaap:InterestExpenseMemberus-gaap:FairValueHedgingMember2022-04-012022-06-300001551152us-gaap:InterestExpenseMemberus-gaap:FairValueHedgingMember2021-04-012021-06-300001551152us-gaap:InterestExpenseMemberus-gaap:FairValueHedgingMember2022-01-012022-06-300001551152us-gaap:InterestExpenseMemberus-gaap:FairValueHedgingMember2021-01-012021-06-300001551152us-gaap:FairValueMeasurementsRecurringMember2022-06-300001551152us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-06-300001551152us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-06-300001551152us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001551152us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001551152us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-06-300001551152us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-06-300001551152us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001551152us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001551152us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-06-300001551152us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-06-300001551152us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001551152us-gaap:FairValueMeasurementsRecurringMember2021-12-310001551152us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310001551152us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310001551152us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001551152us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001551152us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310001551152us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310001551152us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001551152us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001551152us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310001551152us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310001551152us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001551152us-gaap:MeasurementInputDiscountRateMembersrt:MinimumMember2022-06-300001551152us-gaap:MeasurementInputDiscountRateMembersrt:MaximumMember2022-06-300001551152us-gaap:MeasurementInputDiscountRateMembersrt:WeightedAverageMember2022-06-300001551152us-gaap:MeasurementInputDiscountRateMembersrt:MinimumMember2021-12-310001551152us-gaap:MeasurementInputDiscountRateMembersrt:MaximumMember2021-12-310001551152us-gaap:MeasurementInputDiscountRateMembersrt:WeightedAverageMember2021-12-310001551152abbv:ProbabilityofPaymentforUnachievedMilestonesMembersrt:MinimumMember2022-06-300001551152abbv:ProbabilityofPaymentforUnachievedMilestonesMembersrt:MaximumMember2022-06-300001551152srt:WeightedAverageMemberabbv:ProbabilityofPaymentforUnachievedMilestonesMember2022-06-300001551152abbv:ProbabilityofPaymentforUnachievedMilestonesMembersrt:MinimumMember2021-12-310001551152abbv:ProbabilityofPaymentforUnachievedMilestonesMembersrt:MaximumMember2021-12-310001551152srt:WeightedAverageMemberabbv:ProbabilityofPaymentforUnachievedMilestonesMember2021-12-310001551152abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMembersrt:MinimumMember2022-06-300001551152abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMembersrt:MaximumMember2022-06-300001551152srt:WeightedAverageMemberabbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember2022-06-300001551152abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMembersrt:MinimumMember2021-12-310001551152abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMembersrt:MaximumMember2021-12-310001551152srt:WeightedAverageMemberabbv:ProbabilityofPaymentforRoyaltiesbyIndicationMember2021-12-310001551152srt:MinimumMemberabbv:ProjectedYearofPaymentsMember2022-06-300001551152srt:MaximumMemberabbv:ProjectedYearofPaymentsMember2022-06-300001551152srt:WeightedAverageMemberabbv:ProjectedYearofPaymentsMember2022-06-300001551152srt:MinimumMemberabbv:ProjectedYearofPaymentsMember2021-12-310001551152srt:MaximumMemberabbv:ProjectedYearofPaymentsMember2021-12-310001551152srt:WeightedAverageMemberabbv:ProjectedYearofPaymentsMember2021-12-310001551152abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMembersrt:MinimumMember2021-12-310001551152abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMembersrt:MinimumMember2022-06-300001551152abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMembersrt:MaximumMember2022-06-300001551152abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMembersrt:MaximumMember2021-12-310001551152us-gaap:CarryingReportedAmountFairValueDisclosureMember2022-06-300001551152us-gaap:EstimateOfFairValueFairValueDisclosureMember2022-06-300001551152us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2022-06-300001551152us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2022-06-300001551152us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-06-300001551152us-gaap:FairValueInputsLevel1Member2022-06-300001551152us-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310001551152us-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001551152us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2021-12-310001551152us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2021-12-310001551152us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001551152us-gaap:FairValueInputsLevel1Member2021-12-310001551152us-gaap:AccountsReceivableMember2022-01-012022-06-30abbv:wholesaler0001551152us-gaap:GeographicConcentrationRiskMemberabbv:PrincipalUSCustomersMemberus-gaap:AccountsReceivableMember2022-01-012022-06-300001551152us-gaap:GeographicConcentrationRiskMemberabbv:PrincipalUSCustomersMemberus-gaap:AccountsReceivableMember2021-01-012021-12-310001551152us-gaap:ProductConcentrationRiskMemberabbv:HUMIRAMemberus-gaap:SalesRevenueNetMember2022-01-012022-06-300001551152us-gaap:ProductConcentrationRiskMemberabbv:HUMIRAMemberus-gaap:SalesRevenueNetMember2021-01-012021-06-300001551152abbv:SeniorNotesDue2022At3.450PercentMemberus-gaap:SeniorNotesMember2022-01-012022-01-310001551152abbv:SeniorNotesDue2022At3.450PercentMemberus-gaap:SeniorNotesMember2022-01-310001551152us-gaap:LoansPayableMemberabbv:FloatingRateTermLoanTrancheDueMay2025Member2022-02-280001551152us-gaap:LoansPayableMemberabbv:FloatingRateTermLoanTrancheDueMay2025Member2022-02-012022-02-280001551152abbv:FloatingRateTermLoanTrancheDueMay2025RefinancedMemberus-gaap:LoansPayableMember2022-02-280001551152us-gaap:SubsequentEventMemberabbv:SeniorNotesDue2022At3.250PercentMemberus-gaap:SeniorNotesMember2022-07-012022-07-310001551152us-gaap:SubsequentEventMemberabbv:SeniorNotesDue2022At3.250PercentMemberus-gaap:SeniorNotesMember2022-07-310001551152abbv:SeniorNotes2.30PercentDue2021Memberus-gaap:SeniorNotesMember2021-04-012021-04-300001551152abbv:SeniorNotes2.30PercentDue2021Memberus-gaap:SeniorNotesMember2021-04-300001551152abbv:SeniorEuroNotesDue2021At0.500PercentMemberus-gaap:SeniorNotesMember2021-05-012021-05-310001551152abbv:SeniorEuroNotesDue2021At0.500PercentMemberus-gaap:SeniorNotesMember2021-05-310001551152abbv:SeniorNotesDueInMay2021AtFloatingRatesMemberus-gaap:SeniorNotesMember2021-05-012021-05-310001551152us-gaap:PensionPlansDefinedBenefitMember2022-04-012022-06-300001551152us-gaap:PensionPlansDefinedBenefitMember2021-04-012021-06-300001551152us-gaap:PensionPlansDefinedBenefitMember2022-01-012022-06-300001551152us-gaap:PensionPlansDefinedBenefitMember2021-01-012021-06-300001551152us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-04-012022-06-300001551152us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-04-012021-06-300001551152us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-06-300001551152us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-06-300001551152us-gaap:CostOfSalesMember2022-04-012022-06-300001551152us-gaap:CostOfSalesMember2021-04-012021-06-300001551152us-gaap:CostOfSalesMember2022-01-012022-06-300001551152us-gaap:CostOfSalesMember2021-01-012021-06-300001551152us-gaap:ResearchAndDevelopmentExpenseMember2022-04-012022-06-300001551152us-gaap:ResearchAndDevelopmentExpenseMember2021-04-012021-06-300001551152us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300001551152us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-06-300001551152us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-04-012022-06-300001551152us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-04-012021-06-300001551152us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-06-300001551152us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-06-300001551152us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001551152us-gaap:EmployeeStockOptionMember2022-06-300001551152abbv:RestrictedStockUnitsAndPerformanceSharesMember2022-01-012022-06-300001551152abbv:RestrictedStockUnitsAndPerformanceSharesMember2022-06-3000015511522022-06-232022-06-2300015511522021-10-292021-10-2900015511522022-02-172022-02-1700015511522021-09-102021-09-1000015511522021-06-172021-06-1700015511522021-02-182021-02-180001551152abbv:December2018StockRepurchaseAuthorizationMember2022-01-012022-06-300001551152abbv:December2018StockRepurchaseAuthorizationMember2021-01-012021-06-300001551152us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310001551152abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember2021-12-310001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-12-310001551152us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310001551152us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-01-012022-06-300001551152abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember2022-01-012022-06-300001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-01-012022-06-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-01-012022-06-300001551152us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-01-012022-06-300001551152us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300001551152abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember2022-06-300001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-06-300001551152us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300001551152us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2020-12-310001551152abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember2020-12-310001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2020-12-310001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2020-12-310001551152us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2020-12-310001551152us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-01-012021-06-300001551152abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember2021-01-012021-06-300001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-01-012021-06-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-01-012021-06-300001551152us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2021-01-012021-06-300001551152us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-06-300001551152abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember2021-06-300001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-06-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-06-300001551152us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2021-06-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMemberus-gaap:NetInvestmentHedgingMember2022-04-012022-06-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMemberus-gaap:NetInvestmentHedgingMember2021-04-012021-06-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMemberus-gaap:NetInvestmentHedgingMember2022-01-012022-06-300001551152us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMemberus-gaap:NetInvestmentHedgingMember2021-01-012021-06-300001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-04-012022-06-300001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-04-012021-06-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300001551152us-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001551152us-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001551152us-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300001551152us-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:InterestRateSwapMember2022-04-012022-06-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:InterestRateSwapMember2021-04-012021-06-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:InterestRateSwapMember2022-01-012022-06-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:InterestRateSwapMember2021-01-012021-06-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300001551152abbv:NiaspanMember2022-01-012022-06-30abbv:lawsuitabbv:class_actionabbv:direct_purchaserabbv:end_payor_purchaser0001551152abbv:AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember2019-08-012019-08-31abbv:company0001551152abbv:HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember2019-03-012019-05-310001551152abbv:BystolicAntitrustLitigationMember2022-01-012022-06-300001551152abbv:PrescriptionDrugAbuseLitigationMember2022-06-30abbv:claim0001551152abbv:PrescriptionDrugAbuseLitigationInStateCourtsMember2022-06-300001551152us-gaap:SellingGeneralAndAdministrativeExpensesMemberabbv:PrescriptionDrugAbuseLitigationInStateCourtsMember2022-06-300001551152abbv:ElliottAssociatesL.P.Member2016-06-012016-06-30abbv:investment_fund0001551152abbv:ElliottAssociatesL.P.Member2022-02-012022-02-280001551152abbv:ElliottAssociatesL.P.Member2022-01-012022-01-310001551152abbv:ImmunologyMembercountry:USabbv:HUMIRAMember2022-04-012022-06-300001551152abbv:ImmunologyMembercountry:USabbv:HUMIRAMember2021-04-012021-06-300001551152abbv:ImmunologyMembercountry:USabbv:HUMIRAMember2022-01-012022-06-300001551152abbv:ImmunologyMembercountry:USabbv:HUMIRAMember2021-01-012021-06-300001551152abbv:ImmunologyMemberus-gaap:NonUsMemberabbv:HUMIRAMember2022-04-012022-06-300001551152abbv:ImmunologyMemberus-gaap:NonUsMemberabbv:HUMIRAMember2021-04-012021-06-300001551152abbv:ImmunologyMemberus-gaap:NonUsMemberabbv:HUMIRAMember2022-01-012022-06-300001551152abbv:ImmunologyMemberus-gaap:NonUsMemberabbv:HUMIRAMember2021-01-012021-06-300001551152abbv:ImmunologyMemberabbv:HUMIRAMember2022-04-012022-06-300001551152abbv:ImmunologyMemberabbv:HUMIRAMember2021-04-012021-06-300001551152abbv:ImmunologyMemberabbv:HUMIRAMember2022-01-012022-06-300001551152abbv:ImmunologyMemberabbv:HUMIRAMember2021-01-012021-06-300001551152abbv:ImmunologyMembercountry:USabbv:SKYRIZIMember2022-04-012022-06-300001551152abbv:ImmunologyMembercountry:USabbv:SKYRIZIMember2021-04-012021-06-300001551152abbv:ImmunologyMembercountry:USabbv:SKYRIZIMember2022-01-012022-06-300001551152abbv:ImmunologyMembercountry:USabbv:SKYRIZIMember2021-01-012021-06-300001551152abbv:ImmunologyMemberus-gaap:NonUsMemberabbv:SKYRIZIMember2022-04-012022-06-300001551152abbv:ImmunologyMemberus-gaap:NonUsMemberabbv:SKYRIZIMember2021-04-012021-06-300001551152abbv:ImmunologyMemberus-gaap:NonUsMemberabbv:SKYRIZIMember2022-01-012022-06-300001551152abbv:ImmunologyMemberus-gaap:NonUsMemberabbv:SKYRIZIMember2021-01-012021-06-300001551152abbv:ImmunologyMemberabbv:SKYRIZIMember2022-04-012022-06-300001551152abbv:ImmunologyMemberabbv:SKYRIZIMember2021-04-012021-06-300001551152abbv:ImmunologyMemberabbv:SKYRIZIMember2022-01-012022-06-300001551152abbv:ImmunologyMemberabbv:SKYRIZIMember2021-01-012021-06-300001551152abbv:ImmunologyMembercountry:USabbv:RINVOQMember2022-04-012022-06-300001551152abbv:ImmunologyMembercountry:USabbv:RINVOQMember2021-04-012021-06-300001551152abbv:ImmunologyMembercountry:USabbv:RINVOQMember2022-01-012022-06-300001551152abbv:ImmunologyMembercountry:USabbv:RINVOQMember2021-01-012021-06-300001551152abbv:ImmunologyMemberus-gaap:NonUsMemberabbv:RINVOQMember2022-04-012022-06-300001551152abbv:ImmunologyMemberus-gaap:NonUsMemberabbv:RINVOQMember2021-04-012021-06-300001551152abbv:ImmunologyMemberus-gaap:NonUsMemberabbv:RINVOQMember2022-01-012022-06-300001551152abbv:ImmunologyMemberus-gaap:NonUsMemberabbv:RINVOQMember2021-01-012021-06-300001551152abbv:ImmunologyMemberabbv:RINVOQMember2022-04-012022-06-300001551152abbv:ImmunologyMemberabbv:RINVOQMember2021-04-012021-06-300001551152abbv:ImmunologyMemberabbv:RINVOQMember2022-01-012022-06-300001551152abbv:ImmunologyMemberabbv:RINVOQMember2021-01-012021-06-300001551152country:USabbv:HematologicOncologyMemberabbv:ImbruvicaMember2022-04-012022-06-300001551152country:USabbv:HematologicOncologyMemberabbv:ImbruvicaMember2021-04-012021-06-300001551152country:USabbv:HematologicOncologyMemberabbv:ImbruvicaMember2022-01-012022-06-300001551152country:USabbv:HematologicOncologyMemberabbv:ImbruvicaMember2021-01-012021-06-300001551152us-gaap:NonUsMemberabbv:HematologicOncologyMemberabbv:ImbruvicaMember2022-04-012022-06-300001551152us-gaap:NonUsMemberabbv:HematologicOncologyMemberabbv:ImbruvicaMember2021-04-012021-06-300001551152us-gaap:NonUsMemberabbv:HematologicOncologyMemberabbv:ImbruvicaMember2022-01-012022-06-300001551152us-gaap:NonUsMemberabbv:HematologicOncologyMemberabbv:ImbruvicaMember2021-01-012021-06-300001551152abbv:HematologicOncologyMemberabbv:ImbruvicaMember2022-04-012022-06-300001551152abbv:HematologicOncologyMemberabbv:ImbruvicaMember2021-04-012021-06-300001551152abbv:HematologicOncologyMemberabbv:ImbruvicaMember2022-01-012022-06-300001551152abbv:HematologicOncologyMemberabbv:ImbruvicaMember2021-01-012021-06-300001551152abbv:VENCLEXTAMembercountry:USabbv:HematologicOncologyMember2022-04-012022-06-300001551152abbv:VENCLEXTAMembercountry:USabbv:HematologicOncologyMember2021-04-012021-06-300001551152abbv:VENCLEXTAMembercountry:USabbv:HematologicOncologyMember2022-01-012022-06-300001551152abbv:VENCLEXTAMembercountry:USabbv:HematologicOncologyMember2021-01-012021-06-300001551152us-gaap:NonUsMemberabbv:VENCLEXTAMemberabbv:HematologicOncologyMember2022-04-012022-06-300001551152us-gaap:NonUsMemberabbv:VENCLEXTAMemberabbv:HematologicOncologyMember2021-04-012021-06-300001551152us-gaap:NonUsMemberabbv:VENCLEXTAMemberabbv:HematologicOncologyMember2022-01-012022-06-300001551152us-gaap:NonUsMemberabbv:VENCLEXTAMemberabbv:HematologicOncologyMember2021-01-012021-06-300001551152abbv:VENCLEXTAMemberabbv:HematologicOncologyMember2022-04-012022-06-300001551152abbv:VENCLEXTAMemberabbv:HematologicOncologyMember2021-04-012021-06-300001551152abbv:VENCLEXTAMemberabbv:HematologicOncologyMember2022-01-012022-06-300001551152abbv:VENCLEXTAMemberabbv:HematologicOncologyMember2021-01-012021-06-300001551152abbv:AestheticsMemberabbv:BotoxCosmeticMembercountry:US2022-04-012022-06-300001551152abbv:AestheticsMemberabbv:BotoxCosmeticMembercountry:US2021-04-012021-06-300001551152abbv:AestheticsMemberabbv:BotoxCosmeticMembercountry:US2022-01-012022-06-300001551152abbv:AestheticsMemberabbv:BotoxCosmeticMembercountry:US2021-01-012021-06-300001551152abbv:AestheticsMemberabbv:BotoxCosmeticMemberus-gaap:NonUsMember2022-04-012022-06-300001551152abbv:AestheticsMemberabbv:BotoxCosmeticMemberus-gaap:NonUsMember2021-04-012021-06-300001551152abbv:AestheticsMemberabbv:BotoxCosmeticMemberus-gaap:NonUsMember2022-01-012022-06-300001551152abbv:AestheticsMemberabbv:BotoxCosmeticMemberus-gaap:NonUsMember2021-01-012021-06-300001551152abbv:AestheticsMemberabbv:BotoxCosmeticMember2022-04-012022-06-300001551152abbv:AestheticsMemberabbv:BotoxCosmeticMember2021-04-012021-06-300001551152abbv:AestheticsMemberabbv:BotoxCosmeticMember2022-01-012022-06-300001551152abbv:AestheticsMemberabbv:BotoxCosmeticMember2021-01-012021-06-300001551152abbv:AestheticsMembercountry:USabbv:JuvedermCollectionMember2022-04-012022-06-300001551152abbv:AestheticsMembercountry:USabbv:JuvedermCollectionMember2021-04-012021-06-300001551152abbv:AestheticsMembercountry:USabbv:JuvedermCollectionMember2022-01-012022-06-300001551152abbv:AestheticsMembercountry:USabbv:JuvedermCollectionMember2021-01-012021-06-300001551152abbv:AestheticsMemberus-gaap:NonUsMemberabbv:JuvedermCollectionMember2022-04-012022-06-300001551152abbv:AestheticsMemberus-gaap:NonUsMemberabbv:JuvedermCollectionMember2021-04-012021-06-300001551152abbv:AestheticsMemberus-gaap:NonUsMemberabbv:JuvedermCollectionMember2022-01-012022-06-300001551152abbv:AestheticsMemberus-gaap:NonUsMemberabbv:JuvedermCollectionMember2021-01-012021-06-300001551152abbv:AestheticsMemberabbv:JuvedermCollectionMember2022-04-012022-06-300001551152abbv:AestheticsMemberabbv:JuvedermCollectionMember2021-04-012021-06-300001551152abbv:AestheticsMemberabbv:JuvedermCollectionMember2022-01-012022-06-300001551152abbv:AestheticsMemberabbv:JuvedermCollectionMember2021-01-012021-06-300001551152abbv:AestheticsMembercountry:USabbv:OtherAestheticsMember2022-04-012022-06-300001551152abbv:AestheticsMembercountry:USabbv:OtherAestheticsMember2021-04-012021-06-300001551152abbv:AestheticsMembercountry:USabbv:OtherAestheticsMember2022-01-012022-06-300001551152abbv:AestheticsMembercountry:USabbv:OtherAestheticsMember2021-01-012021-06-300001551152abbv:AestheticsMemberus-gaap:NonUsMemberabbv:OtherAestheticsMember2022-04-012022-06-300001551152abbv:AestheticsMemberus-gaap:NonUsMemberabbv:OtherAestheticsMember2021-04-012021-06-300001551152abbv:AestheticsMemberus-gaap:NonUsMemberabbv:OtherAestheticsMember2022-01-012022-06-300001551152abbv:AestheticsMemberus-gaap:NonUsMemberabbv:OtherAestheticsMember2021-01-012021-06-300001551152abbv:AestheticsMemberabbv:OtherAestheticsMember2022-04-012022-06-300001551152abbv:AestheticsMemberabbv:OtherAestheticsMember2021-04-012021-06-300001551152abbv:AestheticsMemberabbv:OtherAestheticsMember2022-01-012022-06-300001551152abbv:AestheticsMemberabbv:OtherAestheticsMember2021-01-012021-06-300001551152abbv:BotoxTherapeuticMembercountry:USabbv:NeuroscienceMember2022-04-012022-06-300001551152abbv:BotoxTherapeuticMembercountry:USabbv:NeuroscienceMember2021-04-012021-06-300001551152abbv:BotoxTherapeuticMembercountry:USabbv:NeuroscienceMember2022-01-012022-06-300001551152abbv:BotoxTherapeuticMembercountry:USabbv:NeuroscienceMember2021-01-012021-06-300001551152us-gaap:NonUsMemberabbv:BotoxTherapeuticMemberabbv:NeuroscienceMember2022-04-012022-06-300001551152us-gaap:NonUsMemberabbv:BotoxTherapeuticMemberabbv:NeuroscienceMember2021-04-012021-06-300001551152us-gaap:NonUsMemberabbv:BotoxTherapeuticMemberabbv:NeuroscienceMember2022-01-012022-06-300001551152us-gaap:NonUsMemberabbv:BotoxTherapeuticMemberabbv:NeuroscienceMember2021-01-012021-06-300001551152abbv:BotoxTherapeuticMemberabbv:NeuroscienceMember2022-04-012022-06-300001551152abbv:BotoxTherapeuticMemberabbv:NeuroscienceMember2021-04-012021-06-300001551152abbv:BotoxTherapeuticMemberabbv:NeuroscienceMember2022-01-012022-06-300001551152abbv:BotoxTherapeuticMemberabbv:NeuroscienceMember2021-01-012021-06-300001551152abbv:VraylarMembercountry:USabbv:NeuroscienceMember2022-04-012022-06-300001551152abbv:VraylarMembercountry:USabbv:NeuroscienceMember2021-04-012021-06-300001551152abbv:VraylarMembercountry:USabbv:NeuroscienceMember2022-01-012022-06-300001551152abbv:VraylarMembercountry:USabbv:NeuroscienceMember2021-01-012021-06-300001551152country:USabbv:DuodopaMemberabbv:NeuroscienceMember2022-04-012022-06-300001551152country:USabbv:DuodopaMemberabbv:NeuroscienceMember2021-04-012021-06-300001551152country:USabbv:DuodopaMemberabbv:NeuroscienceMember2022-01-012022-06-300001551152country:USabbv:DuodopaMemberabbv:NeuroscienceMember2021-01-012021-06-300001551152us-gaap:NonUsMemberabbv:DuodopaMemberabbv:NeuroscienceMember2022-04-012022-06-300001551152us-gaap:NonUsMemberabbv:DuodopaMemberabbv:NeuroscienceMember2021-04-012021-06-300001551152us-gaap:NonUsMemberabbv:DuodopaMemberabbv:NeuroscienceMember2022-01-012022-06-300001551152us-gaap:NonUsMemberabbv:DuodopaMemberabbv:NeuroscienceMember2021-01-012021-06-300001551152abbv:DuodopaMemberabbv:NeuroscienceMember2022-04-012022-06-300001551152abbv:DuodopaMemberabbv:NeuroscienceMember2021-04-012021-06-300001551152abbv:DuodopaMemberabbv:NeuroscienceMember2022-01-012022-06-300001551152abbv:DuodopaMemberabbv:NeuroscienceMember2021-01-012021-06-300001551152country:USabbv:UbrelvyMemberabbv:NeuroscienceMember2022-04-012022-06-300001551152country:USabbv:UbrelvyMemberabbv:NeuroscienceMember2021-04-012021-06-300001551152country:USabbv:UbrelvyMemberabbv:NeuroscienceMember2022-01-012022-06-300001551152country:USabbv:UbrelvyMemberabbv:NeuroscienceMember2021-01-012021-06-300001551152country:USabbv:QuliptaMemberabbv:NeuroscienceMember2022-04-012022-06-300001551152country:USabbv:QuliptaMemberabbv:NeuroscienceMember2021-04-012021-06-300001551152country:USabbv:QuliptaMemberabbv:NeuroscienceMember2022-01-012022-06-300001551152country:USabbv:QuliptaMemberabbv:NeuroscienceMember2021-01-012021-06-300001551152country:USabbv:OtherNeuroscienceMemberabbv:NeuroscienceMember2022-04-012022-06-300001551152country:USabbv:OtherNeuroscienceMemberabbv:NeuroscienceMember2021-04-012021-06-300001551152country:USabbv:OtherNeuroscienceMemberabbv:NeuroscienceMember2022-01-012022-06-300001551152country:USabbv:OtherNeuroscienceMemberabbv:NeuroscienceMember2021-01-012021-06-300001551152us-gaap:NonUsMemberabbv:OtherNeuroscienceMemberabbv:NeuroscienceMember2022-04-012022-06-300001551152us-gaap:NonUsMemberabbv:OtherNeuroscienceMemberabbv:NeuroscienceMember2021-04-012021-06-300001551152us-gaap:NonUsMemberabbv:OtherNeuroscienceMemberabbv:NeuroscienceMember2022-01-012022-06-300001551152us-gaap:NonUsMemberabbv:OtherNeuroscienceMemberabbv:NeuroscienceMember2021-01-012021-06-300001551152abbv:OtherNeuroscienceMemberabbv:NeuroscienceMember2022-04-012022-06-300001551152abbv:OtherNeuroscienceMemberabbv:NeuroscienceMember2021-04-012021-06-300001551152abbv:OtherNeuroscienceMemberabbv:NeuroscienceMember2022-01-012022-06-300001551152abbv:OtherNeuroscienceMemberabbv:NeuroscienceMember2021-01-012021-06-300001551152abbv:LumiganGanfortMembercountry:USabbv:EyeCareMember2022-04-012022-06-300001551152abbv:LumiganGanfortMembercountry:USabbv:EyeCareMember2021-04-012021-06-300001551152abbv:LumiganGanfortMembercountry:USabbv:EyeCareMember2022-01-012022-06-300001551152abbv:LumiganGanfortMembercountry:USabbv:EyeCareMember2021-01-012021-06-300001551152us-gaap:NonUsMemberabbv:LumiganGanfortMemberabbv:EyeCareMember2022-04-012022-06-300001551152us-gaap:NonUsMemberabbv:LumiganGanfortMemberabbv:EyeCareMember2021-04-012021-06-300001551152us-gaap:NonUsMemberabbv:LumiganGanfortMemberabbv:EyeCareMember2022-01-012022-06-300001551152us-gaap:NonUsMemberabbv:LumiganGanfortMemberabbv:EyeCareMember2021-01-012021-06-300001551152abbv:LumiganGanfortMemberabbv:EyeCareMember2022-04-012022-06-300001551152abbv:LumiganGanfortMemberabbv:EyeCareMember2021-04-012021-06-300001551152abbv:LumiganGanfortMemberabbv:EyeCareMember2022-01-012022-06-300001551152abbv:LumiganGanfortMemberabbv:EyeCareMember2021-01-012021-06-300001551152abbv:AlphaganCombiganMembercountry:USabbv:EyeCareMember2022-04-012022-06-300001551152abbv:AlphaganCombiganMembercountry:USabbv:EyeCareMember2021-04-012021-06-300001551152abbv:AlphaganCombiganMembercountry:USabbv:EyeCareMember2022-01-012022-06-300001551152abbv:AlphaganCombiganMembercountry:USabbv:EyeCareMember2021-01-012021-06-300001551152us-gaap:NonUsMemberabbv:AlphaganCombiganMemberabbv:EyeCareMember2022-04-012022-06-300001551152us-gaap:NonUsMemberabbv:AlphaganCombiganMemberabbv:EyeCareMember2021-04-012021-06-300001551152us-gaap:NonUsMemberabbv:AlphaganCombiganMemberabbv:EyeCareMember2022-01-012022-06-300001551152us-gaap:NonUsMemberabbv:AlphaganCombiganMemberabbv:EyeCareMember2021-01-012021-06-300001551152abbv:AlphaganCombiganMemberabbv:EyeCareMember2022-04-012022-06-300001551152abbv:AlphaganCombiganMemberabbv:EyeCareMember2021-04-012021-06-300001551152abbv:AlphaganCombiganMemberabbv:EyeCareMember2022-01-012022-06-300001551152abbv:AlphaganCombiganMemberabbv:EyeCareMember2021-01-012021-06-300001551152country:USabbv:RestasisMemberabbv:EyeCareMember2022-04-012022-06-300001551152country:USabbv:RestasisMemberabbv:EyeCareMember2021-04-012021-06-300001551152country:USabbv:RestasisMemberabbv:EyeCareMember2022-01-012022-06-300001551152country:USabbv:RestasisMemberabbv:EyeCareMember2021-01-012021-06-300001551152us-gaap:NonUsMemberabbv:RestasisMemberabbv:EyeCareMember2022-04-012022-06-300001551152us-gaap:NonUsMemberabbv:RestasisMemberabbv:EyeCareMember2021-04-012021-06-300001551152us-gaap:NonUsMemberabbv:RestasisMemberabbv:EyeCareMember2022-01-012022-06-300001551152us-gaap:NonUsMemberabbv:RestasisMemberabbv:EyeCareMember2021-01-012021-06-300001551152abbv:RestasisMemberabbv:EyeCareMember2022-04-012022-06-300001551152abbv:RestasisMemberabbv:EyeCareMember2021-04-012021-06-300001551152abbv:RestasisMemberabbv:EyeCareMember2022-01-012022-06-300001551152abbv:RestasisMemberabbv:EyeCareMember2021-01-012021-06-300001551152abbv:OtherEyeCareMembercountry:USabbv:EyeCareMember2022-04-012022-06-300001551152abbv:OtherEyeCareMembercountry:USabbv:EyeCareMember2021-04-012021-06-300001551152abbv:OtherEyeCareMembercountry:USabbv:EyeCareMember2022-01-012022-06-300001551152abbv:OtherEyeCareMembercountry:USabbv:EyeCareMember2021-01-012021-06-300001551152us-gaap:NonUsMemberabbv:OtherEyeCareMemberabbv:EyeCareMember2022-04-012022-06-300001551152us-gaap:NonUsMemberabbv:OtherEyeCareMemberabbv:EyeCareMember2021-04-012021-06-300001551152us-gaap:NonUsMemberabbv:OtherEyeCareMemberabbv:EyeCareMember2022-01-012022-06-300001551152us-gaap:NonUsMemberabbv:OtherEyeCareMemberabbv:EyeCareMember2021-01-012021-06-300001551152abbv:OtherEyeCareMemberabbv:EyeCareMember2022-04-012022-06-300001551152abbv:OtherEyeCareMemberabbv:EyeCareMember2021-04-012021-06-300001551152abbv:OtherEyeCareMemberabbv:EyeCareMember2022-01-012022-06-300001551152abbv:OtherEyeCareMemberabbv:EyeCareMember2021-01-012021-06-300001551152country:USabbv:MAVYRETMemberabbv:OtherKeyProductsMember2022-04-012022-06-300001551152country:USabbv:MAVYRETMemberabbv:OtherKeyProductsMember2021-04-012021-06-300001551152country:USabbv:MAVYRETMemberabbv:OtherKeyProductsMember2022-01-012022-06-300001551152country:USabbv:MAVYRETMemberabbv:OtherKeyProductsMember2021-01-012021-06-300001551152us-gaap:NonUsMemberabbv:MAVYRETMemberabbv:OtherKeyProductsMember2022-04-012022-06-300001551152us-gaap:NonUsMemberabbv:MAVYRETMemberabbv:OtherKeyProductsMember2021-04-012021-06-300001551152us-gaap:NonUsMemberabbv:MAVYRETMemberabbv:OtherKeyProductsMember2022-01-012022-06-300001551152us-gaap:NonUsMemberabbv:MAVYRETMemberabbv:OtherKeyProductsMember2021-01-012021-06-300001551152abbv:MAVYRETMemberabbv:OtherKeyProductsMember2022-04-012022-06-300001551152abbv:MAVYRETMemberabbv:OtherKeyProductsMember2021-04-012021-06-300001551152abbv:MAVYRETMemberabbv:OtherKeyProductsMember2022-01-012022-06-300001551152abbv:MAVYRETMemberabbv:OtherKeyProductsMember2021-01-012021-06-300001551152abbv:CreonMembercountry:USabbv:OtherKeyProductsMember2022-04-012022-06-300001551152abbv:CreonMembercountry:USabbv:OtherKeyProductsMember2021-04-012021-06-300001551152abbv:CreonMembercountry:USabbv:OtherKeyProductsMember2022-01-012022-06-300001551152abbv:CreonMembercountry:USabbv:OtherKeyProductsMember2021-01-012021-06-300001551152country:USabbv:LinzessConstellaMemberabbv:OtherKeyProductsMember2022-04-012022-06-300001551152country:USabbv:LinzessConstellaMemberabbv:OtherKeyProductsMember2021-04-012021-06-300001551152country:USabbv:LinzessConstellaMemberabbv:OtherKeyProductsMember2022-01-012022-06-300001551152country:USabbv:LinzessConstellaMemberabbv:OtherKeyProductsMember2021-01-012021-06-300001551152us-gaap:NonUsMemberabbv:LinzessConstellaMemberabbv:OtherKeyProductsMember2022-04-012022-06-300001551152us-gaap:NonUsMemberabbv:LinzessConstellaMemberabbv:OtherKeyProductsMember2021-04-012021-06-300001551152us-gaap:NonUsMemberabbv:LinzessConstellaMemberabbv:OtherKeyProductsMember2022-01-012022-06-300001551152us-gaap:NonUsMemberabbv:LinzessConstellaMemberabbv:OtherKeyProductsMember2021-01-012021-06-300001551152abbv:LinzessConstellaMemberabbv:OtherKeyProductsMember2022-04-012022-06-300001551152abbv:LinzessConstellaMemberabbv:OtherKeyProductsMember2021-04-012021-06-300001551152abbv:LinzessConstellaMemberabbv:OtherKeyProductsMember2022-01-012022-06-300001551152abbv:LinzessConstellaMemberabbv:OtherKeyProductsMember2021-01-012021-06-300001551152abbv:OtherProductsMember2022-04-012022-06-300001551152abbv:OtherProductsMember2021-04-012021-06-300001551152abbv:OtherProductsMember2022-01-012022-06-300001551152abbv:OtherProductsMember2021-01-012021-06-30abbv:segment

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
☒    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2022
OR
☐    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                                    to                                   
Commission File Number: 001-35565
https://cdn.kscope.io/865cf38935582dcd62fda2e2598c1aeb-abbv-20220630_g1.jpg
AbbVie Inc.
(Exact name of registrant as specified in its charter)
Delaware
32-0375147
(State or other jurisdiction of incorporation or organization)
(I.R.S. employer identification number)
1 North Waukegan Road
North Chicago, Illinois 60064-6400
Telephone: (847) 932-7900
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.        Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).        Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer
☒Accelerated Filer☐
Non-Accelerated Filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).        Yes ☐ No ☒
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareABBVNew York Stock Exchange
Chicago Stock Exchange
1.500% Senior Notes due 2023ABBV23BNew York Stock Exchange
1.375% Senior Notes due 2024ABBV24New York Stock Exchange
1.250% Senior Notes due 2024ABBV24BNew York Stock Exchange
0.750% Senior Notes due 2027ABBV27New York Stock Exchange
2.125% Senior Notes due 2028ABBV28New York Stock Exchange
2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange
2.125% Senior Notes due 2029ABBV29New York Stock Exchange
1.250% Senior Notes due 2031ABBV31New York Stock Exchange
As of July 27, 2022, AbbVie Inc. had 1,768,096,495 shares of common stock at $0.01 par value outstanding.


AbbVie Inc. and Subsidiaries
Table of Contents

Page



PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
AbbVie Inc. and Subsidiaries
Condensed Consolidated Statements of Earnings (unaudited)

Three months ended
June 30,		Six months ended
June 30,
(in millions, except per share data)2022202120222021
Net revenues$14,583 $13,959 $28,121 $26,969 
Cost of products sold4,170 4,523 8,222 8,736 
Selling, general and administrative5,412 3,164 8,539 6,006 
Research and development1,609 1,767 3,106 3,434 
Acquired IPR&D and milestones269 132 414 317 
Other operating income(172)(68)(172)(68)
Total operating costs and expenses11,288 9,518 20,109 18,425 
Operating earnings3,295 4,441 8,012 8,544 
Interest expense, net532 606 1,071 1,228 
Net foreign exchange loss47 14 72 23 
Other expense, net1,533 2,658 757 2,263 
Earnings before income tax expense1,183 1,163 6,112 5,030 
Income tax expense255 394 691 706 
Net earnings928 769 5,421 4,324 
Net earnings attributable to noncontrolling interest4 3 7 5 
Net earnings attributable to AbbVie Inc.$924 $766 $5,414 $4,319 
Per share data
Basic earnings per share attributable to AbbVie Inc.$0.52 $0.42 $3.04 $2.42 
Diluted earnings per share attributable to AbbVie Inc.$0.51 $0.42 $3.03 $2.41 
Weighted-average basic shares outstanding1,770 1,769 1,770 1,769 
Weighted-average diluted shares outstanding1,776 1,776 1,777 1,776 

The accompanying notes are an integral part of these condensed consolidated financial statements.
2022 Form 10-Q | https://cdn.kscope.io/865cf38935582dcd62fda2e2598c1aeb-abbv-20220630_g2.gif
1

AbbVie Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Income (unaudited)

Three months ended
June 30,		Six months ended
June 30,
(in millions)2022202120222021
Net earnings$928 $769 $5,421 $4,324 
Foreign currency translation adjustments, net of tax expense (benefit) of $(12) for the three months and $(19) for the six months ended June 30, 2022 and $1 for the three months and $(24) for the six months ended June 30, 2021
(823)244 (1,054)(433)
Net investment hedging activities, net of tax expense (benefit) of $146 for the three months and $183 for the six months ended June 30, 2022 and $(31) for the three months and $72 for the six months ended June 30, 2021
536 (114)666 260 
Pension and post-employment benefits, net of tax expense (benefit) of $11 for the three months and $21 for the six months ended June 30, 2022 and $14 for the three months and $33 for the six months ended June 30, 2021
48 50 76 129 
Cash flow hedging activities, net of tax expense (benefit) of $5 for the three months and $3 for the six months ended June 30, 2022 and $— for the three months and $3 for the six months ended June 30, 2021
27 12 15 58 
Other comprehensive income (loss)(212)192 (297)14 
Comprehensive income716 961 5,124 4,338 
Comprehensive income attributable to noncontrolling interest4 3 7 5 
Comprehensive income attributable to AbbVie Inc.$712 $958 $5,117 $4,333 

The accompanying notes are an integral part of these condensed consolidated financial statements.




2022 Form 10-Q | https://cdn.kscope.io/865cf38935582dcd62fda2e2598c1aeb-abbv-20220630_g2.gif
2

AbbVie Inc. and Subsidiaries
Condensed Consolidated Balance Sheets

(in millions, except share data)June 30,
2022		December 31,
2021
(unaudited)
Assets
Current assets
Cash and equivalents$8,521 $9,746 
Short-term investments1,440 84 
Accounts receivable, net11,237 9,977 
Inventories3,396 3,128 
Prepaid expenses and other4,506 4,993 
Total current assets29,100 27,928 
Investments244 277 
Property and equipment, net4,958 5,110 
Intangible assets, net71,823 75,951 
Goodwill32,028 32,379 
Other assets5,033 4,884 
Total assets$143,186 $146,529 
Liabilities and Equity
Current liabilities
Short-term borrowings$17 $14 
Current portion of long-term debt and finance lease obligations11,913 12,481 
Accounts payable and accrued liabilities22,543 22,699 
Total current liabilities34,473 35,194 
Long-term debt and finance lease obligations61,002 64,189 
Deferred income taxes2,255 3,009 
Other long-term liabilities30,768 28,701 
Commitments and contingencies
Stockholders' equity
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,812,622,099 shares issued as of June 30, 2022 and 1,803,195,293 as of December 31, 2021
18 18 
Common stock held in treasury, at cost, 44,595,448 shares as of June 30, 2022 and 34,857,597 as of December 31, 2021
(4,591)(3,143)
Additional paid-in capital18,906 18,305 
Retained earnings3,516 3,127 
Accumulated other comprehensive loss(3,196)(2,899)
Total stockholders' equity14,653 15,408 
Noncontrolling interest35 28 
Total equity14,688 15,436 
Total liabilities and equity$143,186 $146,529 
The accompanying notes are an integral part of these condensed consolidated financial statements.
2022 Form 10-Q | https://cdn.kscope.io/865cf38935582dcd62fda2e2598c1aeb-abbv-20220630_g2.gif
3

AbbVie Inc. and Subsidiaries
Condensed Consolidated Statements of Equity (unaudited)

(in millions)Common shares outstandingCommon stockTreasury stockAdditional paid-in capitalRetained earningsAccumulated other comprehensive lossNoncontrolling interestTotal
Balance at March 31, 20211,766 $18 $(3,017)$17,712 $2,292 $(3,295)$23 $13,733 
Net earnings attributable to AbbVie Inc.— — — — 766 — — 766 
Other comprehensive income, net of tax— — — — — 192 — 192 
Dividends declared— — — — (2,318)— — (2,318)
Purchases of treasury stock— — (10)— — — — (10)
Stock-based compensation plans and other1 — 5 224 — — — 229 
Change in noncontrolling interest— — — — — — 2 2 
Balance at June 30, 20211,767 $18 $(3,022)$17,936 $740 $(3,103)$25 $12,594 
Balance at March 31, 20221,767 $18 $(4,585)$18,731 $5,103 $(2,984)$31 $16,314 
Net earnings attributable to AbbVie Inc.— — — — 924 — — 924 
Other comprehensive loss, net of tax— — — — — (212)— (212)
Dividends declared— — — — (2,511)— — (2,511)
Purchases of treasury stock— — (9)— — — — (9)
Stock-based compensation plans and other1 — 3 175 — — — 178 
Change in noncontrolling interest— — — — — — 4 4 
Balance at June 30, 20221,768 $18 $(4,591)$18,906 $3,516 $(3,196)$35 $14,688 
Balance at December 31, 20201,765 $18 $(2,264)$17,384 $1,055 $(3,117)$21 $13,097 
Net earnings attributable to AbbVie Inc.— — — — 4,319 — — 4,319 
Other comprehensive income, net of tax— — — — — 14 — 14 
Dividends declared— — — — (4,634)— — (4,634)
Purchases of treasury stock(7)— (797)— — — — (797)
Stock-based compensation plans and other9 — 39 552 — — — 591 
Change in noncontrolling interest— — — — — — 4 4 
Balance at June 30, 20211,767 $18 $(3,022)$17,936 $740 $(3,103)$25 $12,594 
Balance at December 31, 20211,768 $18 $(3,143)$18,305 $3,127 $(2,899)$28 $15,436 
Net earnings attributable to AbbVie Inc.— — — — 5,414 — — 5,414 
Other comprehensive loss, net of tax— — — — — (297)— (297)
Dividends declared— — — — (5,025)— — (5,025)
Purchases of treasury stock(10)— (1,479)— — — — (1,479)
Stock-based compensation plans and other10 31 601 — — 632 
Change in noncontrolling interest— — — — — — 7 7 
Balance at June 30, 20221,768 $18 $(4,591)$18,906 $3,516 $(3,196)$35 $14,688 

The accompanying notes are an integral part of these condensed consolidated financial statements.
2022 Form 10-Q | https://cdn.kscope.io/865cf38935582dcd62fda2e2598c1aeb-abbv-20220630_g2.gif
4

AbbVie Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (unaudited)
Six months ended
June 30,
(in millions) (brackets denote cash outflows)20222021
Cash flows from operating activities
Net earnings$5,421 $4,324 
Adjustments to reconcile net earnings to net cash from operating activities:
Depreciation401 407 
Amortization of intangible assets3,704 4,008 
Deferred income taxes(794)(119)
Change in fair value of contingent consideration liabilities861 2,349 
Stock-based compensation413 428 
Acquired IPR&D and milestones414 317 
Gain on divestitures(172)(68)
Non-cash litigation reserve adjustments, net of cash payments2,190 97 
Other, net(86)(30)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable(1,396)(1,162)
Inventories(499)(249)
Prepaid expenses and other assets14 (281)
Accounts payable and other liabilities(448)308 
Income tax assets and liabilities, net(110)(562)
Cash flows from operating activities9,913 9,767 
Cash flows from investing activities
Acquisitions and investments(394)(345)
Acquisitions of property and equipment(305)(383)
Purchases of investment securities(1,411)(56)
Sales and maturities of investment securities50 65 
Other, net599 135 
Cash flows from investing activities(1,461)(584)
Cash flows from financing activities
Proceeds from issuance of long-term debt2,000 — 
Repayments of long-term debt and finance lease obligations(4,881)(3,461)
Dividends paid(